title: Effect of cetirizine dihydrochloride on the airway response to hypertonic saline aerosol in patients with chronic obstructive pulmonary disease (COPD).
abstract: Hypertonic saline aerosol can elicit airway obstruction in patients with moderate or severe COPD. In the present study we assessed whether cetirizine dihydrochloride is capable of modulating this response. After a screening visit, 20 patients with COPD (mean FEV(1) 49% pred) were treated with cetirizine 10mg daily or placebo over 1 week in a randomized, double-blind, cross-over fashion and measurements performed at the end of treatment periods. At each visit, patients were challenged by 3% saline aerosol (screening: 0.9%) over 5 min after prior inhalation of salbutamol, and 45 min later sputum was obtained after inhalation of 0.9% saline. Lung function was quantified in terms of forced expiratory (FEV(1)) and inspiratory (FIV(1)) volumes. Spirometric values did not differ between visits and salbutamol-induced bronchodilation was not altered by cetirizine. Compared to baseline or post-salbutamol values, the saline-induced fall in FEV(1) was smallest at screening (P<0.01), without a significant difference between treatments. Regarding FIV(1), however, the percent fall from baseline was higher after placebo (Delta=-10.1%; P<0.05) compared to screening (0.4%) or cetirizine (-4.3%). Sputum composition showed no significant differences except for a tendency towards reduced concentrations of alpha(2)-macroglobulin after cetirizine compared to placebo (P=0.045). The present data indicate some, though small, effects of the H1 receptor antagonist cetirizine on hypertonic saline-induced airway obstruction in patients with moderate-to-severe COPD. In view of the mechanisms involved, it is an open question whether stronger effects can be elicited with higher doses and whether such effects would translate into clinical benefits, e.g. during exacerbations.
authors.affiliation: Pulmonary Research Institute, Grosshansdorf, Germany.
authors.forename: Lars
authors.initials: L
authors.lastname: Grönke
authors.forename: Jens
authors.initials: J
authors.lastname: Schlenker
authors.forename: Olaf
authors.initials: O
authors.lastname: Holz
authors.forename: Theo A
authors.initials: TA
authors.lastname: Out
authors.forename: Helgo
authors.initials: H
authors.lastname: Magnussen
authors.forename: Rudolf A
authors.initials: RA
authors.lastname: Jörres
mesh_terms: D000280:Administration, Inhalation; D000368:Aged; D001980:Bronchi / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D017332:Cetirizine / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects*; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D012129:Respiratory Function Tests; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001993:Bronchodilator Agents; D039563:Histamine H1 Antagonists, Non-Sedating; D012462:Saline Solution, Hypertonic; D017332:Cetirizine